Standout Papers

Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or... 2009 2026 2014 2020 433
  1. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study (2009)
    Giancarlo Agnelli, Gualberto Gussoni et al. The Lancet Oncology

Immediate Impact

1 by Nobel laureates 1 from Science/Nature 66 standout
Sub-graph 1 of 21

Citing Papers

Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer
2023 Standout
Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C
2022 Standout
2 intermediate papers

Works of Vito Lorusso being referenced

Effectiveness of bevacizumab added to standard chemotherapy in metastatic colorectal cancer: final results for first-line treatment from the ITACa randomized clinical trial
2015

Author Peers

Author Last Decade Papers Cites
Vito Lorusso 548 270 442 402 59 1.9k
Donald Klippenstein 604 305 865 515 42 2.4k
David Chu 1044 665 139 236 56 2.8k
G. Stehle 687 207 335 206 52 2.0k
Robert T. OʼDonnell 641 492 1131 144 108 2.8k
P. Tanswell 362 295 147 200 51 1.5k
Stewart Spies 559 613 1480 140 79 2.8k
H. Anderson 1400 592 107 184 51 2.7k
Michael A. Savin 1796 694 276 58 60 2.9k
Jamey Skillings 1242 506 147 126 40 2.1k
Olivier Couturier 259 356 743 65 69 1.5k

All Works

Loading papers...

Rankless by CCL
2026